Correct but I am certain those studies are coming next and the problem is BP will position this in the minds of HCP's as THE drug they need to choose along with statins for CAD. ( I can tell by the questioning I am receiving ) . They are connecting the dots between CAD CRF and DM2 bringing them under one common physiology to thereby capture the entire CAD market under the presumption that CAD occurs along this common pathway .
The results showed that the risk reduction of myocardial infarction in the secondary prevention cohort was more significant than that in the primary prevention cohort
AS we all have learned its not about the science ( as long as its not a false narrative) its about the marketing
News 
Market Data 
Discover 
